XML 30 R20.htm IDEA: XBRL DOCUMENT v3.23.3
Stockholders' Equity (Tables)
 9 Months Ended
Sep. 30, 2023
Stockholders' Equity [Abstract]  
Schedule of Changes in Options A summary of the changes in options during the nine months ended September 30, 2023 is as follows:
   Number of
Options		   Weighted
Average
Exercise
Price Per
Share		   Weighted
Average
Remaining
Contractual
Term
(Years)		   Aggregate
Intrinsic
Value		 
Outstanding and expected to vest at December 31, 2022   12,122,606   $18.19    8.5   $417,998 
Granted   690,000   $3.52    9.33   $14,600 
Forfeited   (191,099)  $
-
    
-
   $
-
 
Cancelled   (165,939)  $
-
    
-
   $
-
 
Outstanding  at September 30, 2023   12,455,568   $17.20    7.86   $14,600 
Options exercisable at September 30, 2023   6,559,124   $20.36    7.17   $
-
 
Schedule of Changes in Outstanding Warrants A summary of the changes in outstanding warrants during the nine months ended September 30, 2023 is as follows:
   Number of
Shares		   Weighted
Average
Exercise
Price Per
Share		 
Outstanding at December 31, 2022   3,027,441   $15.24 
Granted   -   $- 
Exercised   -   $- 
Outstanding at September 30, 2023   3,027,441   $15.24 
Warrants vested at September 30, 2023   2,853,816   $16.08 

 
Schedule of Stock-Based Compensation Expense The following table summarizes the components of stock-based compensation expense which includes stock options and warrants in the unaudited consolidated statements of operations for the nine months ended September 30, 2023 and 2022 (rounded to nearest $00):
   Nine Months
Ended
September 30,
2023		   Nine Months
Ended
September 30,
2022		 
Research and development  $5,463,100   $5,674,600 
General and administrative   28,453,800    26,894,200 
Total  $33,916,900   $32,568,800